In a surprising turn of events, the pharmaceutical industry is witnessing a battle of giants as Novo Nordisk, a Danish pharmaceutical company, faces a challenging future due to pricing pressures. The company's CEO, Mike Doustdar, has warned of "unprecedented" price pressures in 2026, causing a slump in its stock prices. But here's where it gets controversial... While the company's annual sales forecast for 2026 showed a decline in revenue, the actual Q4 results for 2025 were slightly better than expected, with sales and diluted EPS figures coming in at $12.3 billion and $0.94, respectively. However, the real controversy lies in the fierce competition from Eli Lilly, who has surpassed Novo Nordisk's sales by Q2 of last year. And this is the part most people miss... As Novo Nordisk launched a new oral GLP-1 for weight loss in January, Eli Lilly is expected to release a weight-loss pill later this year, further intensifying the competition. With patent expiry for semaglutide, the active ingredient in Ozempic and Wegovy, starting this year in major markets like Canada, India, and China, the future looks uncertain for Novo Nordisk. So, what do you think? Do you agree or disagree with the CEO's warning? Share your thoughts in the comments below!
